Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs) and maternal vaccination, both recently recommended by the World Health Organization (WHO), could dramatically alter the […]
Continue reading ->
Health Policy Watch. (2024, December 8). New tools to address RSV, a leading cause of baby hospitalisations. Health Policy Watch. https://healthpolicy-watch.news/new-tools-to-address-rsv-a-leading-cause-of-baby-hospitalisations/
Related news
P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence
500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-Pacific
Julius Clinical Welcomes Bassem Saleh as Chief Executive Officer
Zeist, The Netherlands – September 23, 2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic diseases, is pleased to announce the appointment of Bassem Saleh ...
Julius Clinical spoke to obesity expert Professor Liesbeth van Rossum about the multi-factorial, complex and often misunderstood disease and what the future holds
15 April 2025, The NetherlandsJulius Clinical’s Scientific Officer, Associate Professor Manuel Castro Cabezas, interviewed Professor Liesbeth van Rossum, internist-endocrinologist and professor in the field of obesity at the Erasmus MC, Univ...
